NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2014
At a glance
- Drugs NGR-TNF (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors MolMed
- 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
- 22 Sep 2010 Status changed from active, no longer recruiting to completed, according to a MolMed media release.
- 25 Aug 2010 Positive results of this study have been published in the European Journal of Cancer (doi:10.1016/j.ejca.2010.07.012; published online ahead of print), as reported in a MolMed media release.